有早产史者病史指征环扎与宫颈长度评估预防早产的成本效果
本研究建立决策分析模型,在有早产史人群中比较病史指征环扎策略与经阴道超声宫颈长度评估策略,采用终生时间范围、2022年美元成本及每QALY 10万美元的成本效果阈值。基础病例分析中,病史指征环扎成本更高(85038美元 vs 70155美元),母亲视角(26.74 QALY vs 26.78 QALY)与新生儿视角(28.91 QALY vs 29.06 QALY)效果均略低,净货币效益更低,故被判定为劣势策略。
要点
- 有早产史者中,病史指征环扎成本85038美元,高于宫颈长度评估的70155美元。
- 母亲视角26.74 QALY vs 26.78 QALY,新生儿视角28.91 QALY vs 29.06 QALY,环扎组均略低。
- 蒙特卡洛模拟1000次中,宫颈长度评估在母亲和新生儿视角分别84%和88%的情况下为首选策略。
核心结论
- 在有早产史人群中,病史指征环扎策略较经阴道超声宫颈长度评估策略更昂贵且效果略低,净货币效益更低。
研究设计与样本
- 建立决策分析模型,比较病史指征环扎与宫颈长度评估两种策略。
- 主要结局为母亲与新生儿视角的净货币效益,时间范围为终生,成本以2022年美元计。
- 概率、效用与成本取自文献,成本效果阈值为每QALY 10万美元。
- 先进行单因素敏感性分析,再用蒙特卡洛模拟1000次试验进行概率敏感性分析。
主要发现
- 基础病例分析中,病史指征环扎成本85038美元,宫颈长度评估成本70155美元。
- 母亲视角QALY为26.74 vs 26.78,新生儿视角QALY为28.91 vs 29.06,环扎组均略低。
- 病史指征环扎的母亲与新生儿净货币效益均更低,故该策略被判定为劣势策略。
- 1000次蒙特卡洛模拟中,宫颈长度评估在母亲视角84%、新生儿视角88%的情况下为首选策略。
关键数值与推荐
- 成本效果阈值为每QALY 10万美元。
- 主要结局为母亲与新生儿视角的净货币效益。
- 时间范围为终生,成本单位为2022年美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm birth is one of the major causes of neonatal morbidity and mortality. Preterm delivery is a large burden to our health care system, and a history of preterm birth is one of the most common risk factors for subsequent preterm birth. OBJECTIVE: We sought to examine the cost-effectiveness of the history-indicated cerclage strategy compared with the transvaginal ultrasound cervical length assessment strategy in individuals with a history of preterm birth. STUDY DESIGN: We developed a decision analysis model to compare history-indicated cerclage and cervical length assessment. The primary outcome was the net monetary benefit from a maternal and neonatal perspective of both strategies, defined as the value of an intervention with a known willingness to pay threshold for a unit of benefit. The time horizon was set to be a lifetime. Costs (in 2022 USD) included those for the cerclage, serial transvaginal ultrasounds, maternal care for admission, neonatal care, and severe disability. Probabilities, utilities, and costs were derived from the literature. A cost-effectiveness threshold was set at $100,000 per QALY (quality-adjusted life year). We first conducted 1-way sensitivity analyses with associated variables as sensitivity analyses. We then performed a probabilistic sensitivity analysis using Monte Carlo simulation with 1000 trials to test the robustness of the results in the setting of simultaneous changes in probabilities, costs, and utilities. RESULTS: In our base-case analysis, the history-indicated cerclage strategy compared to transvaginal ultrasound cervical length assessment was associated with more cost ($85,038 vs $70,155), with slightly less effectiveness from the maternal perspective (26.74 QALY vs 26.78 QALY) and from the neonatal perspective (28.91 QALY vs 29.06 QALY), and with less maternal and neonatal net monetary benefit. Therefore, the history-indicated cerclage strategy was dominated. With the 1000 trials of Monte Carlo simulation, transvaginal ultrasound cervical length assessment was the preferred strategy 84% and 88% of the time from the maternal and neonatal perspectives, respectively. CONCLUSION: The history-indicated cerclage strategy was more expensive and slightly less effective than the transvaginal ultrasound cervical length assessment strategy with a lower net monetary benefit.
引用
- Nehme L, Huang JC, Abuhamad A, et al. Cost-effectiveness of history-indicated cerclage vs cervical length assessment for prevention of preterm birth. Am J Obstet Gynecol. 2023. PMID: 37352907. doi:10.1016/j.ajog.2023.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。